ASC's Dr. Ling-Jie Kong will be talking on Gene Editing in T Cells at the CABS Symposium on CAR-T and Cell Therapy | ASC

Applied StemCell’s SVP of Technology Development will be keynote speaker at the Chinese American Bioscience Society (CABS) Symposium on CAR-T and Cell Therapy, to he held on April 6, 2019 at Hanhai BioLabs.

Event Details:

Date: April 6, 2019

Time: 1:00 – 6:00 pm

Venue: Hanhai BioLabs (1633 Bayshore Highway, Suite 280, Burlingame, CA 94010).

Meeting Agenda: http://cabsweb.org/events 

PRESENTATION DETAILS:

By: Dr. Ling-Jie Kong, SVP - Technology Development

Time: 1:30 – 2:15 pm

Title: Gene editing in T-cell therapy.

Abstract: Cancer is one of the leading causes of death worldwide. Patient derived chimeric antigen receptor-T (CAR-T) cells are a powerful tool in achieving a complete remission in a range of B-cell malignancies, most notably B-acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). However, there are limitations. First, the manufacture CAR-T cells from the patient’s own T cells is often challenging and costly. Second, the long process often delays the treatment of the patients. Third, the function of T cell from patients usually are compromised which leads to low response rate in some of the patients.  Healthy donor, gene-edited CAR-T cells which do not require human leucocyte antigen (HLA) matching have the potential to provide an ‘off the shelf’ product, overcoming the manufacturing difficulties of producing CAR-T cells for each individual patient. Here we will present our work towards this goal using iPSc and gene editing technology, focus mainly on our TARGATT technology on gene knock-In.